Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (CHIEF PD)

> Cholinesterase inhibitor (ChEis) are drugs that are currently used to treat people with memory problems in Parkinson's. The effect of these drugs on falls in Parkinson's has been tested to show that treatment

dopamine
  • 55 views
  • 07 Oct, 2022
  • 36 locations
Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease (COALA)

The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with

cholinesterase
donepezil
alzheimer's disease
  • 0 views
  • 08 Jun, 2022
  • 3 locations
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (LUCINDA)

The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of donepezil (Aricept.) Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) …

donepezil
aricept
alzheimer's disease
memantine
dementia
  • 49 views
  • 04 Oct, 2022
  • 1 location
tDCS on Parkinson's Disease Cognition (tDCS-PD-fMRI)

dysfunction is one of the most significant factors affecting the quality of life of patients with PD. While dementia in Parkinson's disease is routinely treated by cholinesterase inhibitors (e.g., donepezil

donepezil
cognitive impairment
brain stimulation
parkinsonism
transcranial direct current stimulation
  • 169 views
  • 20 Apr, 2022
  • 1 location
Istradefylline for Parkinson Disease With Cognitive Impairment

The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.

cognitive impairment
antiparkinsonian agents
istradefylline
carbidopa/levodopa
carbidopa
  • 0 views
  • 04 Oct, 2022
  • 1 location
Cortical Excitability in AD-AHeAD

The aim of this study is to understand the relationship between brain excitability, neuroimaging, and cognitive function in early Alzheimer's disease in order to help develop future treatments. Participants are followed over 18 months.

  • 0 views
  • 03 Mar, 2022
  • 1 location
Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment …

schizophrenia
brief psychotic disorder
schizoaffective disorder
hallucinations
  • 0 views
  • 14 Mar, 2022
  • 1 location
Spinal Cord sTimulation thEraPy for Parkinson's Disease Patients With Gait Problems (STEP-PD)

Gait difficulties are common in Parkinson's disease (PD) and cause significant disability. No treatment is available for these symptoms. Spinal Cord Stimulation (SCS) has been found to improve gait, including freezing of gait, in a small number of PD patients. The mechanism of action is unclear and some patients are …

  • 0 views
  • 05 May, 2022
  • 1 location